drugset / Trial / NCT05242874

Anti-emetic Prophylaxis With or Without Dexamethasone

NCT05242874

Phase 3 Completed 442 enrolled Henan Cancer Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of a fosaprepitant, tropisetron, and olanzapine antiemetic regimen, with or without dexamethasone, in patients receiving highly emetogenic chemotherapy with epirubicin and cyclophosphamide.

Timeline

Start
2022-02-01
Primary completion
2023-08-15
Completion
2023-08-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexamethasone Small molecule 8 mg
Background Fosaprepitant Other / unclassified 150 mg Intravenous
Background Olanzapine Small molecule 5 mg Oral
Background Tropisetron Small molecule 5 mg Intravenous